Diaceutics (LON:DXRX) Reaches New 12-Month High – Still a Buy?

Diaceutics PLC (LON:DXRX)’s stock price hit a new 52-week high on Tuesday. The company traded as high as GBX 199.50 and last traded at GBX 199.50, with a volume of 550495 shares traded. The stock had previously closed at GBX 193.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group restated a “buy” rating and issued a GBX 215 price objective on shares of Diaceutics in a research note on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Diaceutics currently has an average rating of “Buy” and an average target price of GBX 215.

Diaceutics Trading Up 0.2%

The business’s 50-day moving average is GBX 159.51 and its two-hundred day moving average is GBX 154.61. The company has a debt-to-equity ratio of 5.40, a quick ratio of 9.92 and a current ratio of 2.55. The stock has a market capitalization of £170.04 million, a PE ratio of -625.94 and a beta of 0.88.

Diaceutics (LON:DXRX) last announced its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. As a group, equities research analysts anticipate that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.